CMgene: Variation of Genes Controlling Carbohydrate and Lipid Metabolism

Sponsor
Turku University Hospital (Other)
Overall Status
Recruiting
CT.gov ID
NCT03310502
Collaborator
University of Eastern Finland (Other), Kuopio University Hospital (Other), University of Turku (Other)
2,050
1
272.5
7.5

Study Details

Study Description

Brief Summary

Aim of the study is to investigate genes regulating glucose and lipid metabolism in subjects whose glucose metabolism, lipid metabolism, blood flow, or body fat distribution has been measured using positron emission tomography (PET), magnetic resonance imaging (MRI), magnetic resonance spectroscopy (MRS) or computed tomography (CT) as part of their previous participation in clinical trials conducted at Turku PET Centre.

By combining information from PET, MRI, CT, proteomics, metabolomics and genetics analyses we aim to find connection between genetic variation and metabolic and cardiovascular disease.

Detailed Description

The data is collected as a separate part of the clinical imaging study protocols using a separate inform consent approved by the local ethics committee. The participation for this study consists of drawing whole blood, serum and plasma samples for genetics, proteomics and metabolomics analyses. The results from these studies are combined with baseline data from the original clinical imaging studies to find connections between genetic variation, metabolism, blood flow and body fat distribution in a cross-sectional setting.

Study Design

Study Type:
Observational
Anticipated Enrollment :
2050 participants
Observational Model:
Other
Time Perspective:
Cross-Sectional
Official Title:
Variation of Genes Controlling Carbohydrate and Lipid Metabolism
Actual Study Start Date :
Apr 17, 2002
Anticipated Primary Completion Date :
Dec 31, 2022
Anticipated Study Completion Date :
Dec 31, 2024

Outcome Measures

Primary Outcome Measures

  1. Skeletal muscle insulin sensitivity [Baseline]

    Skeletal muscle glucose uptake during euglycemic-hyperinsulinemic clamp (µmol/kg tissue/min)

Secondary Outcome Measures

  1. Whole body insulin sensitivity [Baseline]

    Whole body glucose uptake during euglycemic-hyperinsulinemic clamp (µmol/kg body weight/min)

  2. Visceral adipose tissue insulin sensitivity to glucose uptake [Baseline]

    Visceral adipose tissue glucose uptake during euglycemic-hyperinsulinemic clamp (µmol/kg tissue/min)

  3. Abdominal subcutaneous adipose tissue insulin sensitivity to glucose uptake [Baseline]

    Abdominal subcutaneous adipose tissue glucose uptake during euglycemic-hyperinsulinemic clamp (µmol/kg tissue/min)

  4. Brown adipose tissue insulin sensitivity [Baseline]

    Brown adipose tissue glucose uptake during euglycemic-hyperinsulinemic clamp (µmol/kg tissue/min)

  5. Brown adipose tissue glucose uptake during cold exposure [Baseline]

    Brown adipose tissue glucose uptake during cold exposure (µmol/kg tissue/min)

  6. Insulin sensitivity of adipose tissue lipolysis [Baseline]

    Plasma free fatty acid concentration during euglycemic-hyperinsulinemic clamp (mmol/l)

  7. Myocardial insulin sensitivity [Baseline]

    Myocardial glucose uptake during euglycemic-hyperinsulinemic clamp (µmol/kg tissue/min)

  8. Liver insulin sensitivity to glucose uptake [Baseline]

    Liver glucose uptake during euglycemic-hyperinsulinemic clamp (µmol/kg tissue/min)

  9. Endogenous glucose production [Baseline]

    Endogenous glucose production during euglycemic-hyperinsulinemic clamp (µmol/kg body weight/min)

  10. Brain insulin sensitivity to glucose uptake [Baseline]

    Brain glucose uptake during euglycemic-hyperinsulinemic clamp (µmol/kg tissue/min)

  11. Abdominal subcutaneous adipose tissue mass [Baseline]

    Abdominal subcutaneous adipose tissue mass (kg)

  12. Visceral adipose tissue mass [Baseline]

    Visceral adipose tissue mass (kg)

  13. Liver fat content [Baseline]

    Liver fat percentage (%)

  14. Myocardial fatty acid uptake [Baseline]

    Myocardial fatty acid uptake at fasting state (µmol/kg tissue/min)

  15. Liver fatty acid uptake [Baseline]

    Liver fatty acid uptake at fasting state (µmol/kg tissue/min)

  16. Abdominal subcutaneous adipose tissue fatty acid uptake [Baseline]

    Abdominal subcutaneous adipose tissue fatty acid uptake at fasting state (µmol/kg tissue/min)

  17. Visceral adipose tissue fatty acid uptake [Baseline]

    Visceral adipose tissue fatty acid uptake at fasting state (µmol/kg tissue/min)

  18. Brown adipose tissue fatty acid uptake at fasting state [Baseline]

    Brown adipose tissue fatty acid uptake at fasting state (µmol/kg tissue/min)

  19. Brown adipose tissue fatty acid uptake during cold exposure [Baseline]

    Brown adipose tissue fatty acid uptake at cold exposure (µmol/kg tissue/min)

  20. Skeletal muscle fatty acid uptake [Baseline]

    Skeletal muscle fatty acid uptake at fasting state (µmol/kg tissue/min)

  21. Coronary flow reserve [Baseline]

    Ratio of myocardial blood flow maximum at stress (ml/g/min) vs. myocardial blood flow at rest (ml/g/min)

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Previous participation of studies measuring glucose metabolism, lipid metabolism, bloow flow and adiposity at Turku PET Centre
Exclusion Criteria:

Contacts and Locations

Locations

Site City State Country Postal Code
1 Turku PET Centre (Turku University Hospital) Turku Finland 20521

Sponsors and Collaborators

  • Turku University Hospital
  • University of Eastern Finland
  • Kuopio University Hospital
  • University of Turku

Investigators

  • Principal Investigator: Pirjo R Nuutila, MD, PhD, Turku PET centre, TurkuUH

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Pirjo Nuutila, Professor, chief physician, Turku University Hospital
ClinicalTrials.gov Identifier:
NCT03310502
Other Study ID Numbers:
  • CMgene
First Posted:
Oct 16, 2017
Last Update Posted:
Oct 13, 2021
Last Verified:
Oct 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Pirjo Nuutila, Professor, chief physician, Turku University Hospital
Additional relevant MeSH terms:

Study Results

No Results Posted as of Oct 13, 2021